CRISPR Therapeutics AG (0VRQ.L)
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
$47.88-0.00%
StockGlow Score
Bearish
BearishBullish
1 year ago-14.7%
The outlook
CRISPR Therapeutics AG currently reads as bearish based on below its 50- & 200-day averages, 19% of the way from its 52-week low to high. This is a snapshot of current market data, not a forecast.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range19% of the way from its 52-week low to high
Market cap
—
52-wk high
$91.00
52-wk low
$37.58
50-day avg
$71.57
200-day avg
$58.84
Trailing P/E
0.1